Report from the Annual General Meeting of ChromoGenics AB on 19 May 2022
The annual general meeting of shareholders of ChromoGenics AB was held today on 19 May 2022. The annual general meeting adopted, inter alia, the following resolutions.
Balance sheets and income statements
The annual general meeting adopted the company’s balance sheet and income statement for the financial year 2021.
Disposition regarding the company’s results
The annual general meeting resolved, pursuant to the proposal of the board, that the company’s results be carried forward.
Discharge from liability
The annual general meeting discharged the board members and the managing director as well as the previous managing director Arne Ljungqvist from liability for the financial year 2021.
Remuneration to the board of directors and auditor
The annual general meeting decided that remuneration to chairman of the board of directors shall amount to SEK 200,000 and that remuneration to each of the other directors of the board not employed in the company group shall amount to SEK 100,000.
The annual general meeting decided that remuneration to the auditor shall be paid according to approved invoice.
Election of board members and auditor
The annual general meeting resolved that the board of directors shall consist of four ordinary board members without deputies.
For the period until the end of the next annual general meeting, the annual general meeting elected Johan Hedin, Fredrik Andersson, Mari Broman, Anders Brännström and Andreas Jaeger as board members with Johan Hedin as chairman of the board of directors.
The annual general meeting resolved to elect the registered audit firm Grant Thornton Sweden AB as auditor for the period until the end of the next annual general meeting.
Amendment of the articles of association
The annual general meeting decided to make the following amendments to the articles of association:
- the limits of the share capital, and
- the limits on the number of shares.
Authorisation for the board of directors to decide on new share issues and issues of warrants and/or convertibles
The annual general meeting resolved to authorise the board of directors to resolve, for the period until the end of the next annual general meeting, at one or more occasions and with or without deviation from the shareholders’ preferential rights, to issue new shares, warrants and/or convertibles for cash payment and/or with provision of non-cash consideration or set-off or otherwise. The purpose of the authorisation is the issue of new shares, warrants and/or convertibles to constitute consideration in connection with the acquisition of businesses or financing in connection with the acquisition of businesses, and shall result in an increase of the number of outstanding shares of no more than 30 per cent of the number of outstanding shares.
Nomination Committee
The annual general meeting resolved that the company shall appoint a nomination committee annually for future annual general meetings. The task of the nomination committee shall be to prepare proposals on certain matters to be submitted to the annual general meeting for its approval.
Contact:
Fredrik Fränding, CEO
Tel: +46(0)72 249 24 62
Lars Ericsson, CFO & Head of Communications
Tel: +46 (0)18 430 0430
Email: info@chromogenics.com
ChromoGenics
About ChromoGenics
ChromoGenics is a proptech company that produces dynamic glass for real estate. The company’s product ConverLight® Dynamic, controls indoor comfort with high daylight transmission, great view and solar heat blocking and thereby reduces cost of cooling. ConverLight® Dynamic is based on a patented solution where electrochromic coatings are laminated in plastic film and then laminated between glass. The plastic film is easy to transport, so long shipments of bulky glass can be avoided. ChromoGenics also offers static glass, ConverLight® Static, and the ConverLight® Energy facade glass solution. ChromoGenics’ stock was listed on Nasdaq First North Growth Market in 2017 and has supplied glass technology to several major real estate companies.
ChromoGenics originates from world-leading research at Ångströmlaboratoriet at Uppsala University. The company’s production facility in Uppsala has been partially financed with conditional loans from Energimyndigheten (Energy Authority) in Sweden. ChromoGenics’ share (CHRO) is listed on Nasdaq First North Growth Market with Erik Penser Bank as Certified Adviser: certifiedadviser@penser.se